Syndax to Present Four Revuforj Abstracts at ASCO, Including Post-Transplant Data
SNDX•Syndax secured acceptance of four Revuforj abstracts for ASCO 2026, including an oral presentation of post-transplant maintenance data in 21 adults and children with KMT2Ar, NPM1m or NUP98r acute leukemia. Additional presentations will detail Revuforj’s PK profile with acid-reducing agents and outline ongoing pivotal trial designs.
1. ASCO Abstract Acceptances
Syndax secured acceptance of four Revuforj abstracts for presentation at the ASCO Annual Meeting taking place May 29–June 2, 2026 in Chicago. These include an oral presentation of maintenance data following hematopoietic stem cell transplant and three poster sessions.
2. Post-Transplant Data Overview
The oral session will present safety and efficacy outcomes for 21 adults and children with KMT2Ar, NPM1m or NUP98r acute leukemia receiving Revuforj maintenance post-transplant. Reported metrics include overall survival and relapse rates compared to a historical cohort.
3. Pharmacokinetic Profile Insights
A poster will detail Revuforj’s pharmacokinetics, highlighting its compatibility with gastric acid-reducing agents, clear dose adjustments for strong CYP3A4 inhibitors, and administration with low-fat meals to ensure optimal exposure without compromising efficacy.
4. Ongoing Pivotal Trial Designs
Two additional posters will outline the design of ongoing phase 3 trials combining Revuforj with low- or high-intensity chemotherapy in newly diagnosed NPM1m or KMT2Ar acute leukemia patients ineligible for intensive regimens.
